Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome

Steven Yeh, Eric Suhler, Justine R. Smith, Beau Bruce, Gary Fahle, Steven Bailey, Thomas Hwang, J. Timothy Stout, Andreas (Andy) Lauer, David Wilson, James (Jim) Rosenbaum, Christina Flaxel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: Acute retinal necrosis (ARN) may lead to severe visual loss because of its rapid progression and high likelihood of retinal detachment (RD). This study investigates whether combination systemic and intravitreal antiviral therapy is superior to systemic antiviral therapy alone. PATIENTS AND METHODS: Single-center, interventional, comparative case series of patients with ARN treated with combination systemic antiviral and intravitreal foscarnet injection therapy or systemic antiviral therapy alone. Survival analysis and incidence rates of visual acuity (VA) gain of two lines or greater, severe visual loss of 20/200 or worse, and RD were assessed. RESULTS: Twelve patients received combination therapy and 12 received systemic therapy alone. Patients receiving combination therapy were more likely to gain two or more lines of VA and showed decreased incidences of severe visual loss and RD. CONCLUSION: Combination oral and intravitreal antiviral therapy may improve the likelihood for VA gain and decrease the risk of RD in patients with ARN. Clinicians should consider administering combination systemic and intravitreal antiviral therapy for patients with the ARN syndrome.

Original languageEnglish (US)
Pages (from-to)399-407
Number of pages9
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume45
Issue number5
DOIs
StatePublished - Sep 1 2014

Fingerprint

Acute Retinal Necrosis Syndrome
Antiviral Agents
Retinal Detachment
Visual Acuity
Therapeutics
Foscarnet
Intravitreal Injections
Incidence
Survival Analysis

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery
  • Medicine(all)

Cite this

@article{4ba2de4de7b3453f864cb6b2f326045b,
title = "Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome",
abstract = "BACKGROUND AND OBJECTIVE: Acute retinal necrosis (ARN) may lead to severe visual loss because of its rapid progression and high likelihood of retinal detachment (RD). This study investigates whether combination systemic and intravitreal antiviral therapy is superior to systemic antiviral therapy alone. PATIENTS AND METHODS: Single-center, interventional, comparative case series of patients with ARN treated with combination systemic antiviral and intravitreal foscarnet injection therapy or systemic antiviral therapy alone. Survival analysis and incidence rates of visual acuity (VA) gain of two lines or greater, severe visual loss of 20/200 or worse, and RD were assessed. RESULTS: Twelve patients received combination therapy and 12 received systemic therapy alone. Patients receiving combination therapy were more likely to gain two or more lines of VA and showed decreased incidences of severe visual loss and RD. CONCLUSION: Combination oral and intravitreal antiviral therapy may improve the likelihood for VA gain and decrease the risk of RD in patients with ARN. Clinicians should consider administering combination systemic and intravitreal antiviral therapy for patients with the ARN syndrome.",
author = "Steven Yeh and Eric Suhler and Smith, {Justine R.} and Beau Bruce and Gary Fahle and Steven Bailey and Thomas Hwang and Stout, {J. Timothy} and Lauer, {Andreas (Andy)} and David Wilson and Rosenbaum, {James (Jim)} and Christina Flaxel",
year = "2014",
month = "9",
day = "1",
doi = "10.3928/23258160-20140908-02",
language = "English (US)",
volume = "45",
pages = "399--407",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "5",

}

TY - JOUR

T1 - Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome

AU - Yeh, Steven

AU - Suhler, Eric

AU - Smith, Justine R.

AU - Bruce, Beau

AU - Fahle, Gary

AU - Bailey, Steven

AU - Hwang, Thomas

AU - Stout, J. Timothy

AU - Lauer, Andreas (Andy)

AU - Wilson, David

AU - Rosenbaum, James (Jim)

AU - Flaxel, Christina

PY - 2014/9/1

Y1 - 2014/9/1

N2 - BACKGROUND AND OBJECTIVE: Acute retinal necrosis (ARN) may lead to severe visual loss because of its rapid progression and high likelihood of retinal detachment (RD). This study investigates whether combination systemic and intravitreal antiviral therapy is superior to systemic antiviral therapy alone. PATIENTS AND METHODS: Single-center, interventional, comparative case series of patients with ARN treated with combination systemic antiviral and intravitreal foscarnet injection therapy or systemic antiviral therapy alone. Survival analysis and incidence rates of visual acuity (VA) gain of two lines or greater, severe visual loss of 20/200 or worse, and RD were assessed. RESULTS: Twelve patients received combination therapy and 12 received systemic therapy alone. Patients receiving combination therapy were more likely to gain two or more lines of VA and showed decreased incidences of severe visual loss and RD. CONCLUSION: Combination oral and intravitreal antiviral therapy may improve the likelihood for VA gain and decrease the risk of RD in patients with ARN. Clinicians should consider administering combination systemic and intravitreal antiviral therapy for patients with the ARN syndrome.

AB - BACKGROUND AND OBJECTIVE: Acute retinal necrosis (ARN) may lead to severe visual loss because of its rapid progression and high likelihood of retinal detachment (RD). This study investigates whether combination systemic and intravitreal antiviral therapy is superior to systemic antiviral therapy alone. PATIENTS AND METHODS: Single-center, interventional, comparative case series of patients with ARN treated with combination systemic antiviral and intravitreal foscarnet injection therapy or systemic antiviral therapy alone. Survival analysis and incidence rates of visual acuity (VA) gain of two lines or greater, severe visual loss of 20/200 or worse, and RD were assessed. RESULTS: Twelve patients received combination therapy and 12 received systemic therapy alone. Patients receiving combination therapy were more likely to gain two or more lines of VA and showed decreased incidences of severe visual loss and RD. CONCLUSION: Combination oral and intravitreal antiviral therapy may improve the likelihood for VA gain and decrease the risk of RD in patients with ARN. Clinicians should consider administering combination systemic and intravitreal antiviral therapy for patients with the ARN syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84911422812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911422812&partnerID=8YFLogxK

U2 - 10.3928/23258160-20140908-02

DO - 10.3928/23258160-20140908-02

M3 - Article

C2 - 25215870

AN - SCOPUS:84911422812

VL - 45

SP - 399

EP - 407

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 5

ER -